A Phase 2 interventional study of ACP-196 and ACP-196 in combination with pembrolizumab in Metastatic Pancreatic Cancer, sponsored by Acerta Pharma BV. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-01.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing pembrolizumab in Pancreatic Neoplasms — 5 open to participants now, 9 under way, 1 of them phase 3. pembrolizumab · Pancreatic Neoplasms.
Among the 20 studies testing pembrolizumab in Pancreatic Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 12 in phase 2, and was the 4th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →5 of the 20 studies testing pembrolizumab in Pancreatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 19+
Baylor College of Medicine · Sites in United States
Ages 18+
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–70
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–72
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 1 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 38 across the 20 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
19 studies in Pancreatic Neoplasms by AstraZeneca: 3 open now, 5 under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 19 studies in Pancreatic Neoplasms by AstraZeneca, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2015, is one of 4 in phase 2, and was the 7th registered.
AstraZeneca’s Pancreatic Neoplasms studies by the year they started, since 2002.
3 of the studies testing pembrolizumab in Pancreatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05093231Cambridge University Hospitals NHS Foundation TrustPembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | 2026-11-30 |
| NCT05132504Baylor College of MedicineNeoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | 2027-05-21 |
| NCT05462496Icahn School of Medicine at Mount SinaiModulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing pembrolizumab in Pancreatic Neoplasms, from their registry updates:
Among AstraZeneca’s 19 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACP-196 alone
Drug: ACP-196
ACP-196 in combination with pembrolizumab
Drug: ACP-196 in combination with pembrolizumab
Drug pages: Acalabrutinib · Pembrolizumab
Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: Every 12 weeks for up to 2 years.
| Milestone | Arm 1 - Acalabrutinib Monotherapy | Arm 2- Acalabrutinib+Pembrolizumab |
|---|---|---|
| Started | 37 | 40 |
| Enrolled | 37 | 40 |
| Received study medication | 35 | 38 |
| Discontinued study | 37 | 40 |
| Completed | 0 | 0 |
| Not completed | 37 | 40 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
| Participants | Arm 1 - Acalabrutinib Monotherapy | Arm 2- Acalabrutinib+Pembrolizumab |
|---|---|---|
| Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer. | 0 | 3 |
Collected over AE collected time frame was From the date of the first dose of study drug, through the treatment phase, and within 30 days following the last dose of Acalabrutinib or within 90 days following the last dose of Pembrolizumab.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 - Acalabrutinib Monotherapy | 30/35 (85.7%) | 14/35 (40%) | 34/35 (97.1%) |
| Arm 2- Acalabrutinib+Pembrolizumab | 34/38 (89.5%) | 26/38 (68.4%) | 38/38 (100%) |
| Event | Arm 1 - Acalabrutinib Monotherapy | Arm 2- Acalabrutinib+Pembrolizumab |
|---|---|---|
| Abdominal PainGastrointestinal disorders | 1/35 | 5/38 |
| CholangitisHepatobiliary disorders | 2/35 | 2/38 |
| PneumoniaInfections and infestations | 2/35 | 1/38 |
| HypotensionVascular disorders | 2/35 | 0/38 |
| Atrial FibrillationCardiac disorders | 0/35 | 2/38 |
| VomitingGastrointestinal disorders | 0/35 | 2/38 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/35 | 2/38 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/35 | 2/38 |
| NauseaGastrointestinal disorders | 1/35 | 1/38 |
| Duodenal UlcerGastrointestinal disorders | 1/35 | 0/38 |
| Event | Arm 1 - Acalabrutinib Monotherapy | Arm 2- Acalabrutinib+Pembrolizumab |
|---|---|---|
| Abdominal PainGastrointestinal disorders | 10/35 | 21/38 |
| Decreased AppetiteMetabolism and nutrition disorders | 11/35 | 18/38 |
| FatigueGeneral disorders | 11/35 | 16/38 |
| VomitingGastrointestinal disorders | 6/35 | 15/38 |
| AnaemiaBlood and lymphatic system disorders | 12/35 | 14/38 |
| NauseaGastrointestinal disorders | 8/35 | 14/38 |
| ConstipationGastrointestinal disorders | 8/35 | 13/38 |
| HeadacheNervous system disorders | 11/35 | 11/38 |
| Oedema PeripheralGeneral disorders | 9/35 | 5/38 |
| Abdominal DistensionGastrointestinal disorders | 5/35 | 9/38 |
| Age, Categorical(Participants) | Monotherapy Arm | Combination Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 23 | 43 |
| >=65 years | 15 | 15 | 30 |
| Age, Continuous(Year) | Monotherapy Arm | Combination Arm | Total |
|---|---|---|---|
| Mean | 62.9 ± 8.19 | 61.3 ± 10.94 | 62.1 ± 9.69 |
| Sex: Female, Male(Participants) | Monotherapy Arm | Combination Arm | Total |
|---|---|---|---|
| Female | 18 | 19 | 37 |
| Male | 17 | 19 | 36 |
| Ethnicity (NIH/OMB)(Participants) | Monotherapy Arm | Combination Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 6 |
| Not Hispanic or Latino | 34 | 33 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Monotherapy Arm | Combination Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 29 | 33 | 62 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Region of Enrollment(participants) | Monotherapy Arm | Combination Arm | Total |
|---|---|---|---|
| United States | 35 | 38 | 73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2015 to primary completion in Mar 2017, 22 months.
Results were first posted in Oct 2019, 2 years 7 months after primary completion.
Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 22 months is below that.
Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acalabrutinib · Pembrolizumab